Ivertilene

Ivermectin, the active ingredient in Ivertilene, is an antiparasitic (macrocyclic lactone) presented as an oral tablet for oral use. It treats infections caused by certain parasites such as onchocerciasis, strongyloidiasis and scabies in adults and children as prescribed.

GNH USA supplies Ivertilene as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivertilene is an antiparasitic drug that targets helminthic and ectoparasitic infections. - Onchocerciasis: eliminates the microfilariae responsible for river blindness. - Strongyloidiasis: eradicates intestinal Strongyloides stercoralis larvae. - Scabies: kills the Sarcoptes scabiei mite to resolve skin infestation.

Adverse reactions may occur with Ivertilene use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools during treatment. - Dizziness: transient light‑headedness. - Abdominal pain: cramping or discomfort. - Pruritus: itching sensation. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurologic effects: seizures, ataxia, or altered consciousness. - Hypotension: marked drop in blood pressure. - Hepatic injury: elevated liver enzymes or hepatitis. - Visual disturbances: blurred vision or optic neuritis. - Anaphylaxis: acute allergic reaction requiring emergency care.

Before prescribing Ivertilene, clinicians should consider several safety aspects. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Renal or hepatic impairment: dose adjustment may be required. - Concomitant antiparasitic therapy: monitor for additive toxicity. - Drug interactions: review the patient's medication list for possible interactions. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Ivertilene may interact with other medicines; careful review is advised.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): heightened risk of toxicity.

Moderate Interactions (Monitor Closely): - Benzodiazepines: additive central nervous system depression. - Other antiparasitic agents: cumulative neurotoxicity potential. - Antiretrovirals (e.g., ritonavir): may alter ivermectin metabolism.